deltatrials
Completed PHASE2 NCT00100906

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

Randomized Phase II Trial Of Sequential ATRA Then IL-2 For Modulation Of Dendritic Cells And Treatment Of Metastatic Renal Cancer

Sponsor: Chiron Corporation

Conditions Kidney Cancer
Interventions ATRA IL-2
Updated 6 times since 2017 Last updated: Aug 15, 2013 Started: Aug 31, 2004 Primary completion: Jun 30, 2006 Completion: Jul 31, 2013

A PHASE2 clinical study on Kidney Cancer, this trial is completed. The trial is conducted by Chiron Corporation and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chiron Corporation
  • H. Lee Moffitt Cancer Center and Research Institute
  • National Cancer Institute (NCI)
  • National Institutes of Health (NIH)
Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Tampa, United States